This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Google Scholar Articles by Cosman, F. Articles by Krege, J. H. PubMed PubMed Citation Articles by Cosman, F. Articles by Krege, J. H. Related Collections Calcium and Bone Metabolism Female Endocrinology

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

Helen Hayes Hospital (F.C.), West Haverstraw, New York 10993; Department of Medicine (F.C.), Columbia University College of Physicians and Surgeons, New York, New York 10032; Division of Endocrinology, Metabolism and Nutrition (R.A.W.), Department of Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905; United Osteoporosis Centers (C.R.), Gainesville, Georgia 30506; Department of Medicine (K.F.M.), College of Medicine, Mayo Clinic, Rochester, Minnesota 55905; and Lilly Research Laboratories (L.X., E.V.G., J.H.K.), Eli Lilly and Company, Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Dr. Felicia Cosman, Clinical Research Center, Helen Hayes Hospital, West Haverstraw, New York 10993; or Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032. E-mail: cosmanf{at}helenhayeshosp.org.

Objective: The aim of the study was to assess adding vs. switching to teriparatide 20µg/d in patients on alendronate or raloxifene.

Design: We conducted a randomized, open-label trial.

Patients and Interventions: Postmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.

Main Outcome Measures: We measured bone turnover markers (BTM) and bone mineral density (BMD).

Results: In the alendronate stratum, increases in BTM were smaller in the Add vs. Switch group [6-month PINP (64 vs. 401%); bone ALP (15 vs. 71%); βCTX (27 vs. 250%); all P < 0.001]. However, at 6 months, total hip BMD increased more in the Add vs. Switch group (1.4 vs. –0.8%; P = 0.002). In the Add vs. Switch group, 18-month BMD increments were higher in lumbar spine (8.4 vs. 4.8%; P = 0.003) and total hip (3.2 vs. 0.9%; P = 0.02), but not in femoral neck (2.7 vs. 2.3%; P = 0.75). In the raloxifene stratum, increases in BTM were also smaller in the Add vs. Switch group [6-month PINP (131 vs. 259%; P < 0.001), bone ALP (31 vs. 44%; P = 0.035), and βCTX (67 vs. 144%; P = 0.001)]. At 6 months, total hip BMD increase was greater in the Add vs. Switch group (1.8 vs. 0.5%; P = 0.028). At 18 months, increases in lumbar spine (9.2 vs. 8.1%), total hip (2.8 vs. 1.8%), and femoral neck (3.8 vs. 2.2%) were not significantly different between groups.

Conclusions: In women with osteoporosis treated with antiresorptives, greater bone turnover increases were achieved by switching to teriparatide, whereas greater BMD increases were achieved by adding teriparatide.